Metagenomi Therapeutics Inc
MGX
NASDAQ
Biotechnology
$1.23
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $46.31M
Volume 83.5K
About Metagenomi Therapeutics Inc
The company is headquartered in Emeryville, California and currently employs 119 full-time employees. The company went IPO on 2024-02-09.
CEO
Dr. Jian Irish
HQ
Emeryville, CALIFORNIA, US
Founded
2024
Employees
119
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on MGX.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-59.8%
—
Gross Margin (TTM)
100.0%
0.0 pp
Operating Margin (TTM)
-741.6%
-469.7 pp
Net Margin (TTM)
-689.2%
-431.2 pp
ROE (TTM)
-83.0%
-38.5 pp
Free Cash Flow (TTM)
$-85.80M
—
Financial Snapshot
Revenue
$13.56M
-59.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-93.46M
-7.3%
YoY
Operating Cash Flow
$-85.49M
+11.9%
YoY
Key Statistics
Open
$1.22
Previous Close
$1.23
Day Range
$1.20 - $1.24
52 Week Range
$1.13 - $3.95
Volume
83.5K
Average Volume (10 Days)
130.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$46.31M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
3.41
Price / Book
0.41
Financial Highlights
Profit Margin
-689.2%
Return on Assets
-53.8%
Return on Equity
-83.0%
Revenue (TTM)
$13.56M
Net Income (TTM)
$-93.46M
Diluted EPS (TTM)
-$2.49
Total Cash (MRQ)
$39.03M
Levered FCF (TTM)
$-85.80M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q2 Release
Aug 19
Est. EPS
Adjusted consensus estimate
-$0.58